CA2216856A1 - Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose - Google Patents

Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose

Info

Publication number
CA2216856A1
CA2216856A1 CA002216856A CA2216856A CA2216856A1 CA 2216856 A1 CA2216856 A1 CA 2216856A1 CA 002216856 A CA002216856 A CA 002216856A CA 2216856 A CA2216856 A CA 2216856A CA 2216856 A1 CA2216856 A1 CA 2216856A1
Authority
CA
Canada
Prior art keywords
screening
methods
therapeutic agents
modulating proteins
novel apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002216856A
Other languages
English (en)
Other versions
CA2216856C (fr
Inventor
Philip J. Barr
Michael C. Kiefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2216856A1 publication Critical patent/CA2216856A1/fr
Application granted granted Critical
Publication of CA2216856C publication Critical patent/CA2216856C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002216856A 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose Expired - Lifetime CA2216856C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42652995A 1995-04-20 1995-04-20
US08/426,529 1995-04-20
PCT/US1996/005639 WO1996033416A1 (fr) 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose

Publications (2)

Publication Number Publication Date
CA2216856A1 true CA2216856A1 (fr) 1996-10-24
CA2216856C CA2216856C (fr) 2008-02-19

Family

ID=23691171

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216856A Expired - Lifetime CA2216856C (fr) 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose

Country Status (5)

Country Link
EP (1) EP0821793A1 (fr)
JP (1) JP3615552B2 (fr)
AU (1) AU5568396A (fr)
CA (1) CA2216856C (fr)
WO (1) WO1996033416A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731636B1 (fr) 1993-11-30 2006-01-11 Tanox, Inc. Proteines cdn modulant l'apoptose, adn codant pour ces proteines, et leur mode d'utilisation
WO1998041626A1 (fr) 1997-03-20 1998-09-24 Lxr Biotechnology Inc. NOUVELLE PROTEINE LIANTE Bak, ADN CODANT CETTE PROTEINE ET PROCEDES D'UTILISATION DE CETTE PROTEINE
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
CA2439532A1 (fr) * 2001-03-02 2002-09-26 Mds Proteomics Inc. Methodes et reactifs de regulation de l'apoptose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005738A1 (fr) * 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Agents anticancereux et apoptose
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
EP0731636B1 (fr) * 1993-11-30 2006-01-11 Tanox, Inc. Proteines cdn modulant l'apoptose, adn codant pour ces proteines, et leur mode d'utilisation

Also Published As

Publication number Publication date
EP0821793A1 (fr) 1998-02-04
CA2216856C (fr) 2008-02-19
WO1996033416A1 (fr) 1996-10-24
JP3615552B2 (ja) 2005-02-02
JPH11504423A (ja) 1999-04-20
AU5568396A (en) 1996-11-07

Similar Documents

Publication Publication Date Title
AUPN205095A0 (en) Diagnosis of neuromuscular dysfunction
AU7253796A (en) Novel substituted naphthopyrans
EP0637630A3 (fr) Procédé de préparation biologique de peptides
AU5026490A (en) Ear-focused acoustic lens
AU7246896A (en) Reciprocating bath shaker
AU7380294A (en) Oligopeptide antiretroviral agents
AU6299496A (en) Novel substituted azabicyclic compounds
AU4427296A (en) Novel peptide
AU662683B2 (en) Screening arrangement
AU5965896A (en) Screening assays for compounds
EP0862684A4 (fr) Moteur a disque en nutation
AU5917996A (en) High visibility belt assembly
SG46753A1 (en) Novel sulphonamides
EP0731166A3 (fr) Nouvelles protéines liant le calcium
CA2216856A1 (fr) Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose
AU7130894A (en) Inlet screen
AU7976894A (en) Solventless protein assay standard
AU1449092A (en) Bridge immunoassay
AU4063595A (en) Telescopic bridge plate assembly
AU7742691A (en) Novel protease assays
EP0868590A4 (fr) Assemblage d'elements de dormants
AU4670696A (en) Diagnosis of toxicoinfectious clostridiosis
AU7702796A (en) Polycyclic compounds
AU6988996A (en) 7-azabicyclo(4.2.0)oct-4-en-8-one derivates as plant-microbicides
AU7762694A (en) Screening arrangement

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160419